Compare

Head-to-head.

When two compounds get asked about together. Side-by-side, expert positions, who wins for which goal.

Retatrutide vs Tirzepatide

Both are next-generation GLP-1-based weight loss agents. Retatrutide is the triple agonist (adds glucagon receptor); Tirzepatide is the dual GLP-1/GIP agonist already on market. Choosing between them depends on whether visceral fat or broader GLP-1 receptor benefits matter more.

~5,000 monthly searches

BPC-157 vs TB-500

Both are tissue-repair peptides that get stacked together as the 'Wolverine stack.' BPC-157 works locally near injury sites with broad gut/tendon effect. TB-500 is systemic, mobilizing actin throughout the body for whole-system repair.

~2,500 monthly searches

CJC-1295 vs Sermorelin

Both stimulate the pituitary to release growth hormone naturally — preserving feedback loops, unlike exogenous HGH. CJC-1295 (no-DAC) is the modern preference; Sermorelin is the older, gentler, budget option.

~1,200 monthly searches

Semaglutide vs Tirzepatide

Two GLP-1-based weight loss drugs both FDA-approved. Semaglutide (Wegovy/Ozempic) is the older, single-receptor agonist. Tirzepatide (Mounjaro/Zepbound) adds the GIP receptor — produces more weight loss in head-to-head trials.

~12,000 monthly searches